Physician profile
Mark D Walsh
NPI 1265473813
$1,942.53
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $173 · 2021: $211 · 2022: $427 · 2023: $139 · 2024: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $839.74 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $217.93 | 2019-2022 | |
| Lilly USA, LLC | $189.76 | 2019-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $153.71 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $117.46 | 2019-2024 | Airsupra, Farxiga |
| Amgen INC. | $96.82 | 2019-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.44 | 2023-2024 | Synjardy, Jardiance, Tradjenta |
| Kowa Pharmaceuticals America, INC. | $42.87 | 2019-2022 | |
| Antares Pharma, INC. | $40.95 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.75 | 2022 | |
| Exact Sciences Corporation | $30.10 | 2024 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $18.13 | 2024 | Strensiq |
| Abbott Laboratories | $16.30 | 2024 | Proclaim |
| Sanofi-Aventis U.S. LLC | $15.91 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.77 | 2024 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $14.21 | 2024 | Gvoke Hypopen |
| Abbvie INC. | $13.84 | 2023 | Ubrelvy |
| Esperion Therapeutics, INC. | $13.31 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.69 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.